Jump to content

Clenoliximab

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Boghog (talk | contribs) at 06:41, 29 February 2020 (consistent citation formatting). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Clenoliximab
Monoclonal antibody
TypeWhole antibody
SourceChimeric (primate/human)
TargetCD4
Clinical data
ATC code
  • none
Identifiers
ChemSpider
  • none
 ☒NcheckY (what is this?)  (verify)

Clenoliximab (INN[1]) is a monoclonal antibody against CD4. It acts as an immunomodulator and has been investigated for the treatment of rheumatoid arthritis.[2] The drug is a chimeric antibody from Macaca irus and Homo sapiens.[1]

References

  1. ^ a b World Health Organization (1997). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 77" (PDF). WHO Drug Information. 11 (2): 89.
  2. ^ Hepburn TW, Totoritis MC, Davis CB (January 2003). "Antibody-mediated stripping of CD4 from lymphocyte cell surface in patients with rheumatoid arthritis". Rheumatology. 42 (1): 54–61. doi:10.1093/rheumatology/keg030. PMID 12509613.
Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Clenoliximab&oldid=943161752"